MTOR and cancer: Moreover, it targets the AMP-activated protein kinase alpha 2 (AMPKα2) for ubiquitination and degradation, activating the mammalian target of rapamycin (mTOR)–hypoxia-inducible factor 1-alpha (HIF-1α) axis and promoting cancer progression [55,56].